Evidence map›Paper›PMID 22815702›Full record

Trial reportPloS one2012

Leukocyte telomere length in HIV-infected and HIV-exposed uninfected children: shorter telomeres with uncontrolled HIV viremia.

Hélène C F Côté, Hugo Soudeyns, Anona Thorne, Ariane Alimenti, Valérie Lamarre, Evelyn J Maan, Beheroze Sattha, Joel Singer, Normand Lapointe, Deborah M Money and 12 more

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Role of Monocyte/Macrophages in the Pathogenesis of NeuroHIV.Results and problems in cell differentiation · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 1 country.

Hélène C F CôtéDepartment of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada. helene.cote@ubc.ca
Hugo Soudeyns
Anona Thorne
Ariane Alimenti
Valérie Lamarre
Evelyn J Maan
Beheroze Sattha
Joel Singer
Normand Lapointe
Deborah M Money
John Forbes
CIHR Emerging Team in HIV therapy, aging (CARMA)
Judy Wong
Ari Bitnun
Lindy Samson
Jason Brophy
David Burdge
Neora Pick
Julie van Schalkwyk
Julio Montaner
Marianne Harris
Patti Janssen
Centre Hospitalier Universitaire Sainte-Justine · CAUniversity of British Columbia · CAHIV Legal Network · CAChildren's & Women's Health Centre of British Columbia · CAUniversity of British Columbia Hospital · CAWomen's Health Research Institute · CA

Funding

Canadian Institutes of Health Research HET-85515Canadian Institutes of Health Research MOP-79331Canadian Institutes of Health Research YSH-80511
6 · The paper itself

Abstract

objectivesNucleoside reverse transcriptase inhibitors (NRTIs) used in HIV antiretroviral therapy can inhibit human telomerase reverse transcriptase. We therefore investigated whether in utero or childhood exposure to NRTIs affects leukocyte telomere length (LTL), a marker of cellular aging.

methodsIn this cross-sectional CARMA cohort study, we investigated factors associated with LTL in HIV-1-infected (HIV(+)) children (n = 94), HIV-1-exposed uninfected (HEU) children who were exposed to antiretroviral therapy (ART) perinatally (n = 177), and HIV-unexposed uninfected (HIV(-)) control children (n = 104) aged 0-19 years. Univariate followed by multivariate linear regression models were used to examine relationships of explanatory variables with LTL for: a) all subjects, b) HIV(+)/HEU children only, and c) HIV(+) children only.

resultsAfter adjusting for age and gender, there was no difference in LTL between the 3 groups, when considering children of all ages together. In multivariate models, older age and male gender were associated with shorter LTL. For the HIV(+) group alone, having a detectable HIV viral load was also strongly associated with shorter LTL (p = 0.007).

conclusionsIn this large study, group rates of LTL attrition were similar for HIV(+), HEU and HIV(-) children. No associations between children's LTL and their perinatal ART exposure or HIV status were seen in linear regression models. However, the association between having a detectable HIV viral load and shorter LTL suggests that uncontrolled HIV viremia rather than duration of ART exposure may be associated with acceleration of blood telomere attrition.

Indexed as

AdolescentAnti-HIV AgentsChildChild, PreschoolEnvironmental ExposureFemaleHIV InfectionsHumansInfantLeukocytesLinear ModelsMalePregnancyReverse Transcriptase InhibitorsTelomeraseTelomereAnti-HIV AgentsReverse Transcriptase InhibitorsTelomerase

Identifiers

PMID22815702
PMCPMC3397986
OpenAlexW2028949884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.